non-small-cell

The lung cancer drug, by contrast, blocks an aberrant protein called ALK that is found in only about 5 percent of non-small-cell lung tumors.

Significant Advances in Two of the Hardest to Treat Cancers | Impact Lab 2010

Experts say that even though the drug might be useful for only 5 percent of non-small-cell lung cancer patients, that would still be about 10,000 people a year in the United States and 40,000 worldwide.

Significant Advances in Two of the Hardest to Treat Cancers | Impact Lab 2010

The companies have been developing the drug, motesanib, to be taken with the existing treatments paclitaxel and carboplatin to fight advanced nonsquamous, non-small-cell lung cancer.

Amgen Cancer Drug Fails in Late-Stage Study Matt Jarzemsky 2011

Britain's National Institute for Health and Clinical Excellence, or NICE, said it is upholding an earlier decision not to recommend the daily drug for maintenance use for patients suffering from non-small-cell lung cancer, who have had treatment to stabilize their disease.

Roche Fails in U.K. Drug Appeal Goran Mijuk 2011

Britain's National Institute for Health and Clinical Excellence, or NICE, said it is upholding an earlier decision not to recommend the daily drug for maintenance use for patients suffering from non-small-cell lung cancer, who have had treatment to stabilize their disease.

Roche Fails in U.K. Drug Appeal Goran Mijuk 2011

One is an ALK inhibitor for cancer that works very well in a small subset of non-small-cell lung cancer patients.

Two Pharma Stocks Set For Success Wallace Forbes 2011

The test, called SNaPshot, has been used to identify mutations at more than 50 sites in 14 key genes in patients with non-small-cell lung cancer NSCLC, and is now being offered to patients with a range of other cancers.

Multiple gene test allows more targeted treatment of cancer 2011

Take the case of Metastatic non-small-cell lung cancer.

Zack Cooper: The Case for End-of-Life Care Gets Stronger Zack Cooper 2010

Specifically, evidence has also shown that people with a variety of cancers including breast, lymphoid, cervical, head and neck, and the "non-small-cell" type of lung cancer related to the drugs, died earlier than those who were not taking the ESA drugs.

Anemia drugs deemed risky for people with cancer 2010

Specifically, evidence has also shown that people with a variety of cancers including breast, lymphoid, cervical, head and neck, and the "non-small-cell" type of lung cancer related to the drugs, died earlier than those who were not taking the ESA drugs.

Anemia drugs deemed risky for people with cancer 2010